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Summary
Background Surgical intervention for advanced Parkinson’s disease is an option if medical therapy fails to control 
symptoms adequately. We aimed to assess whether surgery and best medical therapy improved self-reported quality 
of life more than best medical therapy alone in patients with advanced Parkinson’s disease. 
Methods The PD SURG trial is an ongoing randomised, open-label trial. At 13 neurosurgical centres in the UK, between 
November, 2000, and December, 2006, patients with Parkinson’s disease that was not adequately controlled by medical 
therapy were randomly assigned by use of a computerised minimisation procedure to immediate surgery (lesioning or 
deep brain stimulation at the discretion of the local clinician) and best medical therapy or to best medical therapy alone. 
Patients were analysed in the treatment group to which they were randomised, irrespective of whether they received 
their allocated treatment. The primary endpoint was patient self-reported quality of life on the 39-item Parkinson’s 
disease questionnaire (PDQ-39). Changes between baseline and 1 year were compared by use of t tests. This trial is 
registered with Current Controlled Trials, number ISRCTN34111222. 
Findings 366 patients were randomly assigned to receive immediate surgery and best medical therapy (183) or best 
medical therapy alone (183). All patients who had surgery had deep brain stimulation. At 1 year, the mean improvement 
in PDQ-39 summary index score compared with baseline was 5·0 points in the surgery group and 0·3 points in the 
medical therapy group (diﬀ erence –4·7, 95% CI –7·6 to –1·8; p=0·001); the diﬀ erence in mean change in PDQ-39 
score in the mobility domain between the surgery group and the best medical therapy group was –8·9 (95% CI –13·8 
to –4·0; p=0·0004), in the activities of daily living domain was –12·4 (–17·3 to –7·5; p<0·0001), and in the bodily 
discomfort domain was –7·5 (–12·6 to –2·4; p=0·004). Diﬀ erences between groups in all other domains of the 
PDQ-39 were not signiﬁ cant. 36 (19%) patients had serious surgery-related adverse events; there were no suicides but 
there was one procedure-related death. 20 patients in the surgery group and 13 in the best medical therapy group had 
serious adverse events related to Parkinson’s disease and drug treatment. 
Interpretation At 1 year, surgery and best medical therapy improved patient self-reported quality of life more than best 
medical therapy alone in patients with advanced Parkinson’s disease. These diﬀ erences are clinically meaningful, but 
surgery is not without risk and targeting of patients most likely to beneﬁ t might be warranted.
Funding UK Medical Research Council, Parkinson’s UK, and UK Department of Health. 
Introduction
Parkinson’s disease is caused in part by loss of 
dopaminergic neurons in the substantia nigra pars 
compacta; the resultant abnormal neuronal oscillatory 
and synchronous activity between the subthalamic 
nucleus, globus pallidus pars interna, and cerebral cortex 
leads to increasing problems with tremor, rigidity, 
bradykinesia, and postural disturbances.1 Levodopa and 
other dopaminergic drugs relieve these movement 
disorders,2 but dyskinesia and motor ﬂ uctuations develop 
after a few years.
Most neurosurgery for Parkinson’s disease has been 
done on the thalamus, globus pallidus pars interna, or 
subthalamic nucleus, using either lesioning or high 
frequency deep brain stimulation. In recent years, 
advances in imaging have increased the precision of 
surgical interventions; this and advances in the 
understanding of basal ganglia physiology3–5 have meant 
that deep brain stimulation of the subthalamic nucleus 
has been preferred.6
In the late 1990s, there was little reliable evidence from 
randomised trials on the eﬃ  cacy and safety of surgery.7 
Thus, we started the PD SURG trial with the aim of 
comparing the eﬀ ect of surgery with best medical therapy 
in patients with advanced Parkinson’s disease. This 
report presents the results at 1 year’s follow-up.
Methods
Patients
PD SURG is a randomised, open-label trial. Patients 
with Parkinson’s disease for whom current medical 
therapy was not providing adequate symptomatic 
control were eligible. Inclusion criteria were diagnosis 
of Parkinson’s disease according to the UK Brain Bank 
For the trial protocol see http://
www.pdsurg.bham.ac.uk/
investigators/documentation
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criteria,8 age-adjusted score of greater than 5 on the 
dementia rating scale-II (DRS-II),9 and ﬁ tness for 
surgery. 
All patients gave written informed consent before 
randomisation. The trial was approved by the West 
Midlands multicentre research ethics committee and 
local ethics committees at each centre. 
Randomisation and masking
Patients were randomly assigned by a telephone call 
made to the central trial oﬃ  ce. Allocation (1:1) to surgery 
and best medical therapy (surgery group) or best medical 
therapy alone (medical therapy group) was done by use 
of a computerised minimisation procedure with the 
following categories: age at entry (<60, 60–69, and 
≥70 years); years since diagnosis of Parkinson’s disease 
(<5, 5–9, 10–14, and ≥15 years); Hoehn and Yahr stage10 
in the on state (≤2·0, 2·5, 3·0, and ≥4·0); reason for 
considering surgery (tremor, dyskinesia, severe oﬀ 
periods, or other reasons); type of surgery (stimulation 
or lesion) and region to be targeted if allocated to surgery 
(subthalamic nucleus or globus pallidus pars interna); 
and drug therapy to be given if allocated to medical 
therapy (apomorphine or other standard drug treatments 
for Parkinson’s disease). A pair-wise randomisation 
option was available so that centres could enter two 
patients together,11 with one allocated to surgery and one 
to medical therapy. Patients and clinicians were 
unmasked to treatment allocation.
Procedures
Patients allocated to surgery could receive any standard 
procedure in use at the time: either stimulation or 
lesioning of either the subthalamic nucleus or globus 
pallidus pars interna. Surgery was to be done within 
4 weeks of random allocation. The local clinician selected 
the surgical techniques and postoperative management of 
stimulator settings for each patient.
Patients in both groups received medical therapy, 
which could include apomorphine according to local 
practice, other dopamine agonists, monoamine oxidase 
type B inhibitors, catechol-O-methyltransferase inhibitors, 
amantadine, or other drugs for treatment of Parkinson’s 
disease symptoms. Levodopa equivalents were calculated 
on the basis of 100 mg/day of standard levodopa being 
equivalent to the following doses of other drugs: 133 mg 
controlled-release levodopa; 1 mg pergolide, pramipexole, 
cabergoline, or rasagiline; 1·25 mg sublingual selegiline; 
2 mg benzhexol; 3·3 mg rotigotine; 5 mg ropinirole; 10 mg 
bromocriptine, oral selegiline, or apomorphine; and 
100 mg amantadine. The total levodopa dose was multiplied 
by 1·33 for entacapone and by 1·5 for tolcapone.
Apart from the random treatment allocation, all other 
aspects of the management of patients were at the 
discretion of the local clinicians. Patients in the medical 
therapy group could cross over to receive surgery after 
about 1 year.
The primary endpoint was the patient’s self-evaluation of 
their functional status by use of the 39-item Parkinson’s 
disease questionnaire (PDQ-39).12 Secondary endpoints 
included clinical assessment of functioning (uniﬁ ed 
Parkinson’s disease rating scale [UPDRS]13 in both on and 
oﬀ  states) and cognitive status (DRS-II).9 The UPDRS was 
assessed in the on state (on medication) and oﬀ  state (after 
overnight withdrawal of medication) at study entry, and in 
the on state (on medication and on stimulation if surgery 
was done) and oﬀ  state (after overnight withdrawal of 
medication but on stimulation if surgery was done) at 
follow-up. Neuropsychological assessments were also done 
in a subset of patients and involved a clinical interview and 
a battery of 16 psychometric tests and questionnaires. 
Neuropsychological assessment could not be done on all 
patients because trained examiners were not available in 
some centres. For centres that did not have trained 
examiners, a similar method to that used in a previous 
multicentre randomised controlled trial was 
adopted:14 where possible, psychologists (who were based, 
trained, and supervised centrally in Oxford) visited the 
centres to complete assessments as required. We collected 
data on the type and dose of drug treatments for Parkinson’s 
disease and on the incidence of serious adverse events 
(deﬁ ned as any event that resulted in a prolonged stay in 
hospital or admission to hospital, was thought to be life-
threatening, or resulted in death). Data on serious adverse 
events was collected on serious adverse events forms, 
annual follow-up forms (completed by the local clinician), 
resource usage forms (completed by the patients), and 
Figure 1: Trial proﬁ le
PDQ-39=39-item Parkinson’s disease questionnaire. STN=subthalamic nucleus. DBS=deep brain stimulation. 
GPi=globus pallidus pars interna. *1 patient who refused surgery then withdrew from the trial. †As slots for surgery 
became available around the 1 year timepoint they were used for patients in the medical therapy group. In one case, 
a slot became available earlier and the treating clinician decided to cross this patient over early (at 10 months).
183 allocated to surgery
         178 had surgery
                  174 had STN DBS
                       4 had GPi DBS
              5 did not have surgery
                  3 refused*
                  1 died
                  1 unﬁt for anaesthesia
183 allocated to medical therapy
         171 had medical therapy
           12 had surgery within 1 year
                 3 wanted to have surgery, so paid 
for surgery themselves
                 6 unable to cope on medication
                 1 deteriorated
                 1 needed Parkinson’s disease 
                    controlled before knee operation
                 1 slot became available for surgery†
366 randomly assigned
     21 had no PDQ-39 data available 
           for analysis at 1 year
              1 refused surgery
              2 died
           18 forms not returned
162 had PDQ-39 data available for analysis
         at 1 year
153 had PDQ-39 data available for analysis 
         at 1 year
     30 had no PDQ-39 data available 
           for analysis at 1 year
             4 withdrew
                 1 fell and broke neck
                 1 had dementia
                 2 withdrew consent
              1 died
           25 forms not returned
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partial review of medical notes and information from 
family doctors. Data for non-serious adverse events was 
also collected for patients in the surgery group by use of 
post-operation forms (one immediately after surgery and 
one 6 months later) and subsequent annual follow-up 
forms. Patients in both groups were to be assessed at 1, 2, 
3, 5, 7, and 9 years after randomisation. Here, we present 
data from the 1-year follow-up.
Statistical analysis
PD SURG was designed to detect a ten-point diﬀ erence 
(regarded as clinically important) between groups in the 
PDQ-39 summary index. Assuming a standard deviation 
of 30 (two-sided p of 0·05 and 90% power), this required 
random allocation of about 400 patients in total.
An independent data monitoring committee reviewed 
eﬃ  cacy and safety data annually. If large diﬀ erences 
between the groups were observed, the data monitoring 
committee could recommend to the independent trial 
steering committee that enrolment to the trial be stopped 
early or modiﬁ ed as appropriate.
Patients were analysed in the treatment group to which 
they were randomised, irrespective of whether they 
received their allocated treatment, although patients 
without follow-up at 1 year could not be included in the 
analysis. For continuous variables, changes from baseline 
to 1 year were compared between the groups using t tests. 
Missing values in PDQ-39 domain scores were imputed 
by use of the expectation maximisation algorithm.15 
Categorical data were analysed using χ² tests or Fisher’s 
exact tests. Subgroup analyses by protocol-speciﬁ ed 
stratiﬁ cation parameters were done to explore diﬀ erences 
in treatment eﬀ ect across subgroups, using tests of 
heterogeneity or tests for trend. Analyses were done using 
SAS version 9.1 (Cary, NC, USA).
This trial is registered with Current Controlled Trials, 
number ISRCTN34111222.
Role of the funding source
The study funding sources were not involved in the 
study design, data collection, data analysis, data 
interpretation, or the writing of the report, nor were they 
involved in the decision to submit the paper for 
publication. The manufacturers of the stimulators used 
in the trial had no role in the design, data collection, data 
analysis, data interpretation, writing of the report, or the 
decision to submit the paper for publication. The views 
expressed in this Article do not necessarily reﬂ ect those 
of the funding bodies. All authors had full access to the 
study data, read and approved the ﬁ nal version of the 
paper, and were responsible for the decision to submit 
the paper for publication.
Results
Between November, 2000, and December, 2006, 366 patients 
from 13 neurosurgical centres in the UK were randomly 
assigned to the surgery group or to the best medical therapy 
group (183 per group, ﬁ gure 1). Baseline characteristics 
were similar between groups (tables 1, 2, and 3). 348 of 
366 patients were aged less than 70 years (mean age 
59 years) and 341 patients had had Parkinson’s disease for 
at least 5 years (mean duration 11·4 years). Dyskinesia 
(n=267) and severe oﬀ  periods (n=280) were the most 
common reasons for considering surgery (table 1). In 
addition to levodopa, 357 of 366 patients had received 
previous therapy with a dopamine agonist, 197 with a 
monoamine oxidase type B inhibitor, 214 with a catechol-O-
methyltransferase inhibitor, and 145 with apomorphine 
(90 were still on apomorphine at random allocation).
Five patients in the surgery group did not have surgery: 
three refused surgery, one was unﬁ t for anaesthesia, and 
one died before surgery (ﬁ gure 1). 81 of 178 patients had 
Surgery (n=183) Medical therapy (n=183)
Demographics
Age (years) 59 (37–79) 59 (36–75)
Men 125 (68%) 135 (74%)
Baseline characteristics
Duration of Parkinson’s disease (years) 11·5 (2·0–32·2) 11·2 (1·0–30·0)
Hoehn and Yahr stage (on state) 
≤2 66 (36%) 68 (37%)
2·5 58 (32%) 55 (30%)
3 54 (30%) 54 (30%)
4 5 (3%) 6 (3%)
5 0 (0%) 0 (0%)
Hoehn and Yahr stage (oﬀ  state)* 
≤2 12 (7%) 11 (6%)
2·5 19 (11%) 29 (16%)
3 65 (38%) 59 (34%)
4 54 (32%) 55 (31%)
5 19 (11%) 22 (13%)
Previous treatment†
Dopamine agonist 179 (98%) 178 (97%)
Monoamine oxidase type B inhibitor 99 (54%) 98 (54%)
Catechol-O-methyltransferase inhibitor 103 (56%) 111 (61%)
Apomorphine 72 (39%) 73 (40%)
On apomorphine at study entry 45 (25%) 45 (25%)
Reason for considering surgery†
Tremor 73 (40%) 73 (40%)
Dyskinesia 134 (73%) 133 (73%)
Severe oﬀ  periods 141 (77%) 139 (76%)
Other‡ 16 (9%) 17 (9%)
PDQ-39 summary index 37·5 (14·6) 38·7 (13·7)
UPDRS part III: motor (on) 18·9 (11·4) 20·1 (11·4)
UPDRS part III: motor (oﬀ ) 47·6 (14·0) 48·6 (14·3)
Data are mean (range), number (%), or mean (SD). UPDRS=uniﬁ ed Parkinson’s disease rating scale. PDQ=Parkinson’s 
disease questionnaire. *Based on baseline UPDRS part IV: complications of therapy, where patients are asked what their 
worst Hoehn and Yahr stage had been in the past week. Data were available for 169 of 183 patients in the surgery 
group and 176 of 183 patients in the medical therapy group. †Not mutually exclusive: more than one previous 
treatment and reason for considering surgery could apply. ‡Including motor complications (ﬂ uctuations or dystonia, 
n=12), rigidity (n=7), bradykinesia (n=5), gait problems (n=4), intolerance to drugs (n=3), goose stepping (n=1), and 
pain (n=1). Percentage values do not add up to 100 in some cases because of rounding. 
Table 1: Demographics and baseline characteristics
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surgery within 4 weeks of random allocation, 66 within 
4–8 weeks, 22 within 8–16 weeks, and nine more than 
16 weeks after random allocation. All 178 patients in the 
surgery group who received surgery had deep brain 
stimulation and in 174 the subthalamic nucleus was the 
surgical target. 176 of 178 procedures were bilateral; there 
Baseline 1 year Change between baseline and 1 year
Surgery 
(n=178)
Medical 
therapy 
(n=178)
Surgery 
(n=162)
Medical 
therapy 
(n=153)
Diﬀ erence in means 
at 1 year (95% CI)
p Surgery 
(n=160)
Medical 
therapy 
(n=150)
Diﬀ erence in the mean 
change (95% CI)
p
Summary index 37·5 (14·6) 38·7 (13·7) 32·5 (15·8) 38·1 (13·5) –5·6 (–8·9 to –2·4) 0·0008 –5·0 (14·1) –0·3 (11·1) –4·7 (–7·6 to –1·8) 0·001
Mobility 56·3 (22·5) 60·1 (22·4) 48·1 (25·2) 60·2 (23·6) –12·0 (–17·5 to –6·6) <0·0001 –8·2 (24·8) 0·7 (18·9) –8·9 (–13·8 to –4·0) 0·0004
Activities of daily living 49·6 (21·4) 51·4 (20·4) 37·0 (21·6) 51·0 (21·1) –14·0 (–18·7 to –9·3) <0·0001 –12·3 (23·6) 0·1 (20·3) –12·4 (–17·3 to –7·5) <0·0001
Emotional wellbeing 31·3 (19·7) 31·0 (19·5) 27·9 (21·1) 28·6 (18·8) –0·7 (–5·1 to 3·8) 0·77 –3·3 (20·9) –1·2 (16·2) –2·1 (–6·3 to 2·1) 0·33
Stigma 33·2 (25·2) 37·2 (26·0) 25·5 (24·2) 35·0 (24·6) –9·5 (–14·9 to –4·1) 0·0006 –8·1 (24·4) –3·0 (21·9) –5·2 (–10·4 to 0·03) 0·05
Social support 18·8 (19·0) 16·6 (20·9) 19·2 (20·5) 16·8 (19·3) 2·4 (–2·1 to 6·8) 0·30 0·6 (18·4) 0·5 (19·3) 0·1 (–4·1 to 4·4) 0·95
Cognition 30·4 (19·7) 29·6 (20·5) 28·6 (21·3) 30·0 (19·4) –1·4 (–5·9 to 3·1) 0·54 –1·7 (19·7) 1·4 (19·2) –3·0 (–7·4 to 1·3) 0·17
Communication 31·9 (23·1) 31·7 (23·1) 34·3 (23·0) 33·0 (21·0) 1·3 (–3·6 to 6·2) 0·61 2·9 (22·3) 1·6 (18·0) 1·4 (–3·2 to 5·9) 0·55
Bodily discomfort 48·9 (23·1) 52·1 (23·8) 39·2 (23·7) 50·0 (23·0) –10·9 (–16·1 to –5·7 ) <0·0001 –9·8 (23·1) –2·4 (22·6) –7·5 (–12·6 to –2·4) 0·004
Data are mean (SD). The PDQ-39 range is 0–100; the higher the score, the worse the self-reported quality of life; negative change=improvement. Ten baseline forms and 51 1-year forms were not returned. 
Five patients returned 1-year PDQ-39 forms, but did not return baseline PDQ-39 forms, so we were unable to calculate a change from baseline for these patients. Missing values in PDQ-39 domain scores were 
imputed using the expectation maximisation algorithm. PDQ-39=39-item Parkinson’s disease questionnaire. 
Table 2: Primary outcome (PDQ-39)
Baseline 1 year Change between baseline and 1 year
Surgery Medical 
therapy
Surgery Medical 
therapy
Diﬀ erence in means 
at 1 year (95% CI)
p Surgery Medical 
therapy
Diﬀ erence in the mean 
change (95% CI)
p
n Mean 
(SD)
n Mean 
(SD)
n Mean 
(SD)
n Mean 
(SD)
n Mean 
(SD)
n Mean 
(SD)
UPDRS*
Part I: mental 176 2·3 
(1·7)
181 2·2 
(1·6)
154 2·3 
(1·8)
151 2·5 
(1·7)
–0·2 (–0·6 to 0·2) 0·29 148 –0·01 
(1·8)
149 0·3 
(1·6)
–0·3 (–0·7 to 0·1) 0·15
Part II: activities of 
daily living (on)
170 9·9 
(6·5)
172 10·3 
(6·0)
150 9·9 
(5·9)
146 10·9 
(6·5)
–1·0 (–2·4 to 0·4) 0·16 142 0·3 
(6·4)
138 1·0 
(5·1)
–0·6 (–2·0 to 0·7) 0·36
Part II: activities of 
daily living (oﬀ )
162 23·8 
(7·2)
167 24·7 
(7·3)
130 17·6 
(8·1)
139 23·9 
(7·6)
–6·3 (–8·2 to –4·4) <0·0001 123 –6·9 
(7·2)
129 –0·5 
(5·9)
–6·4 (–8·0 to –4·7) <0·0001
Part III: motor (on) 165 18·9 
(11·4)
164 20·1 
(11·4)
146 16·0 
(8·8)
136 20·4 
(10·8)
–4·5 (–6·8 to –2·2) 0·0001 135 –3·3 
(9·4)
124 0·8 
(9·1)
–4·0 (–6·3 to –1·8) 0·0006
Part III: motor (oﬀ ) 161 47·6 
(14·0)
162 48·6 
(14·3)
126 30·6 
(15·2)
135 47·3 
(15·4)
–16·6 (–20·4 to –12·9) <0·0001 119 –17·2 
(13·1)
123 –0·4 
(13·3)
–16·8 (–20·1 to –13·4) <0·0001
Part IV: complications 
of therapy
145 9·0 
(3·4)
145 9·1 
(3·4)
119 4·5 
(3·1)
118 9·0 
(3·7)
–4·6 (–5·4 to –3·7) <0·0001 106 –4·4 
(3·8)
112 –0·2 
(2·8)
–4·2 (–5·1 to –3·3) <0·0001
Total (I–III) score (on) 161 30·9 
(16·6)
159 32·6 
(16·3)
141 28·1 
(13·8)
132 34·0 
(15·6)
–5·9 (–9·5 to –2·4) 0·001 128 –2·8 
(14·2)
116 2·5 
(11·5)
–5·4 (–8·6 to –2·1) 0·002
Total (I–III) score (oﬀ ) 155 73·1 
(19·7)
158 75·7 
(20·0)
121 50·9 
(21·3)
127 73·3 
(21·7)
–22·4 (–27·8 to –17·1) <0·0001 114 –23·7 
(17·5)
113 –0·5 
(18·0)
–23·2 (–27·9 to –18·6) <0·0001
Total (I–IV) score (on) 136 39·6 
(17·8)
129 39·5 
(15·4)
111 32·7 
(14·6)
107 41·6 
(16·3)
–8·9 (–13·0 to –4·7) <0·0001 95 –6·6 
(15·3)
91 1·6 
(12·2)
–8·3 (–12·3 to –4·3) <0·0001
Total (I–IV) score (oﬀ ) 137 81·5 
(21·4)
132 83·6 
(21·0)
100 55·6 
(22·4)
105 81·9 
(24·3)
–26·3 (–32·8 to –19·9) <0·0001 89 –27·4 
(18·9)
91 –0·9 
(20·1)
–26·6 (–32·3 to –20·9) <0·0001
Cognition†
DRS-II 159 10·7 
(2·8)
156 10·4 
(2·9)
126 10·6 
(3·2)
144 10·1 
(3·0)
0·5 (–0·3 to 1·2) 0·20 121 –0·4 
(3·5)
133 –0·4 
(2·9)
0·05 (–0·7 to 0·8) 0·90
UPDRS=uniﬁ ed Parkinson’s disease rating scale. DRS-II=dementia rating scale II. *177 patients in the surgery group and 181 in the medical therapy group were assessed at baseline, and 155 in the surgery group and 
152 in the medical therapy group were assessed at 1 year. Data on 150 patients in each group were included in assessments of mean changes between baseline and 1 year. The numbers analysed for each part of the 
UPDRS are diﬀ erent because of missing data. There are no imputation methods for the UPDRS. UPDRS score ranges: mental 0–16; activities of daily living 0–52; motor 0–108; complications 0–23; total (parts I–III) 
0–176; total (parts I–IV) 0–199 (high scores=worse clinical assessment of the patient’s Parkinson’s disease). UPDRS negative change=improvement. †When the trial started patients were allowed to complete either 
the mini-mental state examination or DRS-II; therefore data on the DRS-II were not available for all patients. DRS-II range: 0–18 (high score=better cognitive function). DRS-II negative change=deterioration.
Table 3: UPDRS and DRS-II scores
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was one staged procedure with electrodes implanted 
10 months apart. 
In the medical therapy group, 12 patients had surgery 
between baseline and 1  year (ﬁ gure 1), of whom three 
received surgery between 10 months and 12 months after 
random allocation but completed 1-year assessments 
before surgery. 118 patients randomly allocated to medical 
therapy had surgery at or after 1 year.
The mean change between baseline and 1 year on the 
PDQ-39 summary index was –5·0 points in the surgery 
group and –0·3 points in the medical therapy group 
(diﬀ erence –4·7 points, 95% CI –7·6 to –1·8, p=0·001; 
table 2). The mean change in PDQ-39 summary index 
between baseline and 1 year ranged from less than –30 to 
more than 30 (ﬁ gure 2). The diﬀ erence in mean change in 
score between baseline and 1 year was –8·9 for the PDQ-39 
domain of mobility (95% CI –13·8 to –4·0; p=0·0004), 
–12·4 for activities of daily living (–17·3 to –7·5; p<0·0001), 
–7·5 for bodily discomfort (–12·6 to –2·4; p=0·004), 
and –5·2 for stigma (–10·4 to 0·03; p=0·05).
For the PDQ-39 summary index score, there was no 
evidence that the size of the treatment eﬀ ect in favour of 
surgery varied with age, duration of Parkinson’s disease, 
Hoehn and Yahr stage, reasons for considering surgery, 
or whether apomorphine treatment was planned 
(ﬁ gure 3). Full details of the subgroup analyses will be 
reported elsewhere.
The mean UPDRS (on) total (parts I–IV) score 
decreased between baseline and 1 year by 6·6 points in 
the surgery group (ie, improvement) and increased by 
1·6 points in the medical therapy group (diﬀ erence 
–8·3 points, 95% CI –12·3 to –4·3; p<0·0001; table 3). 
The diﬀ erence in the mean change between baseline and 
1 year between the groups was –4·0 (95% CI –6·3 to –1·8; 
p=0·0006) for the motor (on) subsection of the UPDRS 
and –4·2 (–5·1 to –3·3; p<0·0001) for the complications 
of therapy subsection. The mean UPDRS (oﬀ ) total (parts 
I–IV) score decreased between baseline and 1 year by 
27·4 points in the surgery group and by 0·9 points in the 
medical therapy group (diﬀ erence –26·6 points, 95% CI 
–32·3 to –20·9; p<0·0001). We investigated the answers 
to UPDRS questions relating speciﬁ cally to dyskinesia 
and oﬀ  periods because these were the two main reasons 
that patients were considered for surgery. At 1 year, 
75 patients in the surgery group and 21 in the medical 
therapy group reported no waking day dyskinesia 
(p<0·0001) and 45 in the surgery group and ﬁ ve in the 
medical therapy group reported no oﬀ  time (p<0·0001; 
table 4).
The DRS-II score decreased by 0·4 points 
(ie, deterioration) between baseline and 1  year in both 
groups (diﬀ erence 0·05, 95% CI –0·7 to 0·8, p=0·90; 
table 3). 39 measures were compared in the 
neuropsychological assessments on up to 163 patients. 
The Delis-Kaplan executive function system phonemic 
mean score decreased by 6·5 points (SD 9·4) between 
baseline and 1 year in the surgery group and decreased by 
0·6 points (8·7) in the medical therapy group (diﬀ erence 
–5·9, 95% CI –8·9 to –2·9; p=0·0002). The mean change 
in score on the D-KEFS categorical verbal ﬂ uency between 
baseline and 1 year was –4·5 points (SD 7·8) in the surgery 
group and –0·2 (7·7) in the medical therapy group 
(diﬀ erence –4·4, –6·9 to –1·8; p=0·001). On the Wechsler 
abbreviated scale of intelligence vocabulary, the mean 
change from baseline to 1 year was –1·5 (4·8) in the 
surgery group and 0·6 (4·9) in the medical therapy group 
(diﬀ erence –2·1, –3·7 to –0·5; p=0·01).
At 1 year, patients in the surgery group were on a mean 
levodopa equivalent dose of 894 mg/day (SD 568) and 
those in the medical therapy group were on 1347 mg/day 
(585, p<0·0001). This diﬀ erence of 453 mg/day (95% CI 
Figure 2: Mean change in 39-item Parkinson’s disease questionnaire summary index score between baseline 
and 1 year
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Baseline 1 year
Surgery Medical therapy p* Surgery Medical therapy p*
Dyskinesia
n 177 180 0·93 155 151 <0·0001
None 19 (11%) 27 (15%) ·· 75 (48%) 21 (14%) ··
1–25% 71 (40%) 63 (35%) ·· 65 (42%) 56 (37%) ··
26–50% 55 (31%) 55 (31%) ·· 10 (6%) 44 (29%) ··
51–75% 26 (15%) 27 (15%) ·· 4 (3%) 27 (18%) ··
76–100% 6 (3%) 8 (4%) ·· 1 (1%) 3 (2%) ··
Oﬀ  time
n 175 180 0·40 154 152 <0·0001
None 6 (3%) 2 (1%) ·· 45 (29%) 5 (3%) ··
1–25% 66 (38%) 68 (38%) ·· 83 (54%) 64 (42%) ··
26–50% 85 (49%) 88 (49%) ·· 23 (15%) 63 (41%) ··
51–75% 16 (9%) 20 (11%) ·· 3 (2%) 17 (11%) ··
76–100% 2 (1%) 2 (1%) ·· 0 (0%) 3 (2%) ··
Based on UPDRS part IV: complications of therapy (Q32: what proportion of the waking day is dyskinesia present? 
Q39: what proportion of the waking day is the patient oﬀ  on average?). *χ2 test for the difference between the surgery 
group and the medical therapy group across all categories. 
Table 4: Dyskinesia and oﬀ  periods
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328 to 580) at 1 year represents a 34% reduction in mean 
drug dose in the surgery group compared with the 
medical therapy group.
At baseline, 45 patients in each group were on 
apomorphine. By 1  year, this had decreased to 13 in the 
surgery group (ten were on apomorphine at baseline and 
three started on apomorphine after random allocation) and 
had increased to 63 in the medical therapy group (34 were 
on apomorphine at baseline and 29 started on apomorphine 
after randomisation). Of the patients on apomorphine at 
1 year, 54 patients were on continuous drug infusions (six 
in the surgery group and 48 in the medical therapy group) 
and 22 were on intermittent dosing (seven in the surgery 
group and 15 in the medical therapy group).
36 of 178 patients in the surgery group had 43 surgery-
related serious adverse events. There were no serious 
Figure 3: Subgroup analyses of 39-item Parkinson’s disease questionnaire summary index score 
Age
<60 years 83 –6·2 (1·6) 78 –0·9 (1·4) –5·3 4·5 –9·5 to –1·1
60–69 years 69 –3·6 (1·7) 64 –0·3 (1·2) –3·3 4·3 –7·4 to 0·8
≥70  years 8 –4·1 (3·3) 8 5·6 (3·5) –9·7 22·6 –19·0 to –0·4
Subtotal 160  150  –4·8 2·0  –7·5 to –2·0
Test for trend: χ2₁=0·0; p=0·83
Duration of Parkinson’s disease
<10 years 66 –5·9 (2·0) 64 –1·2 (1·6) –4·7 6·2 –9·6 to 0·2
10–14 years 56 –5·0 (1·7) 57 0·9 (1·2) –5·9 4·2 –9·9 to –1·9
≥15  years 38 –3·2 (2·2) 29 –0·6 (2·1) –2·6 9·3 –8·6 to 3·4
Subtotal 160  150  –4·8 2·0  –7·6 to –2·1
Test for trend: χ2₁=0·2; p=0·67
Hoehn and Yahr stage
≤Stage 2 57 –2·9 (2·1) 55 –0·8 (1·2) –2·1 5·9 –6·9 to 2·7
Stage 2·5 52 –5·3 (1·7) 44 –0·5 (1·4) –4·8 5·0 –9·2 to –0·4
≥Stage 3 51 –6·9 (1·9) 51 0·4 (2·0) –7·3 7·6 –12·7 to –1·9
Subtotal 160  150  –4·5 2·0  –7·3 to –1·8
Test for trend: χ2₁=2·0; p=0·16
Reason for surgery: tremor
No 97 –5·0 (1·5) 87 0·1 (1·3) –5·1 3·9 –9·0 to –1·2
Yes 63 –4·9 (1·6) 63 –0·8 (1·3) –4·1 4·3 –8·2 to 0·0
Subtotal 160  150  –4·6 2·0  –7·4 to –1·8
Test for heterogeneity: χ2₁=0·1; 2p=0·73
Reason for surgery: dyskinesia
No 43 –2·5 (2·2) 41 –1·4 (1·7) –1·1 7·9 –6·6 to 4·4
Yes 117 –5·9 (1·3) 109 0·1 (1·1) –6·0 2·8 –9·3 to –2·7
Subtotal 160  150  –4·7 2·1  –7·5 to –1·9
Test for heterogeneity: χ2₁=2·2; 2p=0·13
Reason for surgery: severe oﬀ-periods
No 35 –4·8 (2·3) 38 –0·8 (1·4) –4·0 7·3 –9·3 to 1·3
Yes 125 –5·0 (1·3) 112 –0·1 (1·1) –4·9 2·9 –8·2 to –1·6
Subtotal 160  150  –4·6 2·1  –7·5 to –1·8
Test for heterogeneity: χ2₁=0·1; 2p=0·78
Plan to prescribe apomorphine
No 32 –3·9 (3·0) 34 0·6 (1·5) –4·5 11·4 –11·1 to 2·1
Yes 128 –5·2 (1·2) 116 –0·5 (1·1) –4·7 2·6 –7·9 to –1·5
Subtotal 160  150  –4·7 2·1  –7·5 to –1·8
Test for heterogeneity: χ2₁=0·96; 2p=0·78
Total 160  150  –4·7 2·1  –7·5 to –1·9
 Number Mean (SD) Number Mean (SD)
 Surgery Medical therapy
 Change from baseline  Diﬀerence Variance Diﬀerence (95% CI)
–20 100–10 20
Favours surgery Favours medical therapy
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adverse events in the 12 patients in the medical therapy 
group who received surgery in the ﬁ rst year. The most 
common surgery-related serious adverse events were 
infections (n=16; table 5).
There were 39 Parkinson’s disease-related and drug-
related serious adverse events reported in 33 patients 
(25 events in 20 patients in the surgery group and 14 in 
13 patients in the medical therapy group), the most 
common of which were worsening of Parkinson’s disease 
symptoms or uncontrolled Parkinson’s disease symptoms 
(12 events in 11 patients in the surgery group and two in 
the medical therapy group; table 5). There was one 
unsuccessful postoperative suicide attempt in a patient in 
the surgery group; however, this patient had previously 
attempted suicide before trial entry. Three patients died 
during the ﬁ rst year: one from haemorrhage during 
surgery, one in the surgery group from pneumonia 3 weeks 
after study entry before surgery was done, and one from 
stroke in the medical therapy group 10 months after entry.
Discussion
PD SURG was designed with quality of life as the primary 
endpoint to examine the eﬃ  cacy of deep brain stimulation 
versus medical therapy on the daily lives of people with 
Parkinson’s disease and thus provide practical information 
to inform future use. PD SURG included a representative 
sample of patients likely to be oﬀ ered surgery at 
neuroscience centres in the UK, where apomorphine is 
readily available, thus enabling comparison of surgery with 
best medical therapy and providing evidence on the 
beneﬁ ts of surgery in a real-world setting. The follow-up 
reported here was longer than in two other large trials of 
deep brain stimulation versus medical therapy,16,17 and thus 
gives statistically more reliable results and provides 
evidence on the longer term beneﬁ ts of surgery (with less 
likelihood of a so-called honeymoon eﬀ ect18 in the period 
just after surgery). Although one trial has investigated the 
eﬀ ects of surgery for Parkinson’s disease to 18 months, 
only 20 patients were included and thus the trial was 
underpowered; also, patients with earlier stage disease 
were recruited.19 
From a purely scientiﬁ c perspective, a long-term trial 
of surgery versus medical therapy would have been 
ideal; however, a realistic design acceptable to both 
patients and clinicians was necessary, and so surgery 
was permitted after 1 year in the medical therapy group. 
There were clear advantages for surgery compared with 
medical therapy alone at 1 year, both in patient-assessed 
quality of life and on clinical assessment. These beneﬁ ts 
are likely to be meaningful to patients, as measured by 
use of the PDQ-39,20 and were found in domains of the 
PDQ-39 that surgery would be expected to aﬀ ect (eg, 
mobility and activities of daily living), but not in others 
(eg, social support, cognition, and communication). 
These ﬁ ndings were mirrored by clinically meaningful 
diﬀ erences on the UPDRS,21 including the patient-rated 
UPDRS part IV, which showed substantial beneﬁ ts of 
surgery in the time and severity of dyskinesia and oﬀ  
periods—the most common reasons for patients to be 
considered for surgery. Greater beneﬁ ts for the surgery 
group than the medical therapy group were seen for 
oﬀ -medication UPDRS assessments. However, this 
represents an artiﬁ cial situation, created by a temporary 
withdrawal of medication and does not indicate an 
absence of drug because the washout period was not 
long enough. When considering the real-life 
on-medication assessment, the magnitude of the beneﬁ t 
Surgery (n=183) Medical therapy (n=183)
Surgery-related 43 events in 36 patients 0 events in 12 patients*
Haemorrhage 4 (including 1 death)† 0
Infection 16 0
DBS-speciﬁ c adverse events 13 events in 12 patients 0
Postoperative confusion 5 0
Neck pain 2 0
Seizures 2 0
Deteriorating control of Parkinson’s disease 
because battery was switched oﬀ 
1 0
Psychosis 1 0
Unresponsive on operating table (possibly 
because of levodopa withdrawal)
1 0
Visual neglect from oedema 1 0
General surgery problems 10 events in 9 patients 0 events
Urinary retention 4 0
Pulmonary embolism 2 0
Anxiety attack 1 0
Diﬃ  culty removing catheter 1 0
Postoperative hypotension 1 0
Pyrexia 1 0
Parkinson’s-disease related and drug-related 25 events in 20 patients 14 events in 13 patients 
Falls 3 7
Constipation 4 in 3 patients 2
Worsening of Parkinson’s disease symptoms or 
uncontrolled Parkinson’s disease symptoms
12 in 11 patients 2
Psychiatric problems 4 1
Neuropsychiatric disturbances (including 
hallucinations or paranoia)
3 0
Breakdown 0 1
Suicide attempt 1 0
Parkinson’s disease drug-related 2 2
Other 26 events‡ in 19 patients 14 events§ in 13 patients
Deaths 2 (haemorrhage and 
pneumonia)
1 (stroke)
Total 96 events in 65 patients 29 events in 26 patients 
Serious adverse events were any event that prolonged a patient’s stay in hospital, resulted in the patient being admitted 
to hospital, was considered to be life-threatening, or resulted in death. DBS=deep brain stimulation. *12 patients 
randomly assigned to medical therapy received surgery between baseline and 1 year. †One patient had a haemorrhage 
5 months after surgery and this was probably not treatment related. ‡Five urinary problems; ﬁ ve leg swelling or knee 
swelling, or both; three pain; two chest pain or angina; two chest infection; one collapse; one deep vein thrombosis 
(more than 8 months after surgery); one pulmonary embolism (more than 8 months after surgery); one polymyalgia 
rheumatica; one vertigo; one renal colic; one fainting episode; one lacerated wound to forearm; and one head injury. 
§Four chest pain or angina; two urinary problems; two pain; one abscess on chest wall leading to infection; one deep 
vein thrombosis; one cauda equina syndrome; one fainting episode; one confusion; and one chest problems. 
Table 5: Serious adverse events in the ﬁ rst year
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seen in our trial is smaller than perhaps anticipated 
from the numerous small uncontrolled series that have 
suggested large eﬀ ects of surgery.22,23
PD SURG, along with other reported randomised 
trials,16,17,19 shows beneﬁ ts for surgery over best medical 
treatment in patients with advanced Parkinson’s disease, 
even when apomorphine is available, while also 
conﬁ rming that there are risks associated with surgery. A 
meta-analysis of PDQ-39 summary index scores showed 
that the results of the trials are generally consistent with 
each other (test for heterogeneity, p=0·2; ﬁ gure 4), 
although there is evidence of heterogeneity of treatment 
eﬀ ect between the trials with 6 months of follow-up and 
PD SURG with 12 months of follow-up (test for 
interaction, p=0·04).
The PD SURG results at 1 year show smaller diﬀ erences 
between the groups in the PDQ-39 summary index 
(4·7 points) than was seen in the two trials that reported 
results after 6 months (8·7 points).16,17 Although from a 
statistical perspective this diﬀ erence is not substantial and 
might be a chance eﬀ ect, it is worth considering potential 
alternative explanations based on diﬀ erences in the trial 
designs. First, it is possible that there is a large immediate 
eﬀ ect of surgery, whether real or in part related to an early 
so-called honeymoon eﬀ ect,18 which gradually decreases 
over time. If the beneﬁ ts of surgery are relatively transient, 
this would call into question the long-term value of surgery. 
Second, there might have been better drug treatment of 
Parkinson’s disease in the medical group of PD SURG 
than in the other two trials, because of the use of 
apomorphine in over one-third of patients in this group. 
Apomorphine is an eﬀ ective drug in advanced Parkinson’s 
disease2 and can be given by continuous infusion to enable 
a more constant dose to be delivered to the patient, thereby 
smoothing out on–oﬀ  periods and ﬂ uctuations. However, 
apomorphine is expensive, and thus in the UK tends to be 
used only when other drugs have failed to control the 
symptoms of Parkinson’s disease adequately; that is, it 
might be used in the same situations as surgery for 
patients with advanced Parkinson’s disease. Hence, a 
comparison of the eﬀ ects of surgery plus medical therapy 
versus medical therapy, in a population of patients whose 
treatment could have included apomorphine (as in PD 
SURG), provides better evidence on the relative beneﬁ ts of 
surgery than a comparison with medical therapy not 
including apomorphine. However, apomorphine is less 
widely used outside the UK, and was not reported as being 
widely used in the other trials.16,17 Administration of 
apomorphine is more complicated than for other 
Parkinson’s disease drugs, requiring infusion and 
monitoring. Nevertheless, because of its eﬃ  cacy, 
apomorphine use might become more common, and thus 
the results of PD SURG could have wider relevance in 
future. Optimisation of medical therapy might lead to a 
smaller comparative advantage for surgery. Nevertheless, 
surgery is still a valid treatment because patients would 
need to have only a one-oﬀ  procedure (albeit with need for 
stimulator adjustment and replacement) rather than 
regular administration of an expensive drug. Whether 
technical aspects of the procedure, such as electrode 
location within the target site, are factors that could be 
improved are also important to consider.24,25 
Substantially more patients in the surgery group had 
serious adverse events than did patients in the medical 
therapy group, conﬁ rming that deep brain stimulation 
surgery for Parkinson’s disease is not without risks.26,27 
Reporting of all serious adverse events, whether surgery 
related, disease related, or drug related, was mandatory in 
both the surgical and medical groups. Because a 6-month 
postoperation form that included serious adverse events 
was completed only in the surgical group, there could 
have been diﬀ erential reporting of serious adverse events 
Figure 4: Meta-analysis of 39-item Parkinson’s disease questionnaire summary index score in trials of deep brain stimulation versus medical therapy
6 months
Deuschl and colleagues16 71 –9·5 (1·8) 73 0·2 (1·3)                           –9·7                   5·0 –14·1 to –5·3
Weaver and colleagues17 121 –7·7 (1·3) 134 0·4 (1·1)                           –8·1                   3·1 –11·6 to –4·6
Subtotal 192  207                                                       –8·7                    1·9  –11·4 to –6·0
Test for heterogeneity: χ2₁=0·3; 2p=0·58
12 months
PD SURG 160 –5·0 (1·1) 150 –0·3 (0·9)                          –4·7                    2·1 –7·5 to –1·9
18 months
Schüpbach and colleagues19 10 –6·5 (3·3) 10 4·0 (3·1)                        –10·5                 20·0 –19·3 to –1·7
Total                                              362                                           367                                                         –7·0                    0·9                                                                                                                       –8·9 to –5·0
Test for heterogeneity (4 trials): χ2₃=5·0; 2p=0·17
Test for trend between subtotals: χ2₁=1·5; 2p=0·22
 Number Mean (SD) Number Mean (SD)
 Surgery Medical therapy
 Change from baseline  Diﬀerence Variance                                        Diﬀerence (95% CI)
–30 200–20 30
Favours surgery Favours medical therapy
–10 10
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unrelated to surgery, despite eﬀ orts—through a case-note 
review—to collect these data in both groups. However, 
similar surgery-related serious adverse events were seen 
in the two other trials.16,17 Furthermore, recently raised 
concerns about the suicide rate27–29 after surgery were not 
conﬁ rmed in our study (only one patient attempted 
suicide after surgery), and only one patient died as a result 
of the procedure. A limitation of the study is that adverse 
events that were not serious enough to cause or prolong a 
patient’s stay in hospital were not routinely recorded. 
However, adverse events are diﬃ  cult to record accurately 
(eg, there were three times more adverse events in one of 
two comparable trials than in the other)16,17 and their 
combined eﬀ ects should be reﬂ ected in the participants’ 
perception of their quality of life.
Preliminary analysis of the neuropsychological outcomes, 
to be reported in detail elsewhere, did not suggest any 
major adverse eﬀ ect of surgery other than on verbal ﬂ uency 
and vocabulary. The changes in group means for 
neuropsychological outcomes represent small decreases in 
individual scores that are not usually associated with 
clinically meaningful eﬀ ects on any activities of daily 
living.30 Subclinical decreases in verbal ﬂ uency after deep 
brain stimulation or lesional surgery for Parkinson’s 
disease have been reported,31–33 and are understood to be 
caused by disruption to projections from the basal ganglia 
to the prefrontal cortex, which are involved in language and 
executive skills. For example, after deep brain stimulation 
of the subthalamic nucleus, substantial associations have 
been reported between activation of areas including the 
dorsolateral prefrontal cortex and Broca’s area, as measured 
with ﬂ uorine-18-labelled-ﬂ uoro deoxy glucose-PET, and 
performance on verbal ﬂ uency tasks.33 These changes are 
not associated with patient age, disease duration, or dose of 
dopaminomimetic drugs after surgery;34 however, a 
frequency-dependent reciprocal modulation of verbal 
ﬂ uency and motor functions in deep brain stimulation of 
the subthalamic nucleus has been reported.34 
Discussions with potential candidates for surgery 
should include the potential risks and beneﬁ ts of surgery. 
Deep brain stimulation is a costly procedure and therefore 
health economic issues need to be taken into account. 
However, the amount of drug therapy required in the 
surgery group was about one third lower than the amount 
required by those in the medical therapy group. Thus, the 
cost of surgery will be partly oﬀ set by the reduction in the 
amount of drug therapy required by patients who have 
had surgery. In particular, if apomorphine or continuous 
intestinal infusions of levodopa, with high recurrent 
costs, are the alternative drug treatment options, the cost-
eﬀ ectiveness equation might favour surgery (a full 
economic analysis of PD SURG will be reported 
elsewhere). Thus, it is important to identify patients who 
are or are not likely to beneﬁ t from surgery when the 
risks and costs are taken into account. Subgroup analyses 
are unreliable, with a high likelihood of chance eﬀ ects 
being observed.35 The protocol-speciﬁ ed subgroup 
analyses did not provide clear evidence that the beneﬁ t of 
surgery diﬀ ered in diﬀ erent types of patient, although, 
given the insensitivity of tests for interaction,36 the 
possible greater beneﬁ t in patients with more advanced 
disease, as measured by Hoehn and Yahr stage (p=0·2), is 
worthy of further investigation. 
Some limitations in the design of PD SURG should be 
acknowledged, especially in relation to a potential placebo 
eﬀ ect. Ideally, patients and assessors would have been 
masked to treatment allocation. However, sham surgery 
on patients in the medical therapy group (ie, to insert 
electrodes and stimulators but not switch them on) would 
not have been practical (eg, increased theatre time and 
cost). Furthermore, attempts at masking are likely to be 
ineﬀ ective because, in many cases, patients will be able 
to tell if their stimulator is switched on. Thus, patients’ 
perception of their quality of life could have been 
inﬂ uenced by their knowledge of the treatment they 
received. Use of independent masked assessors was 
beyond the resources available for this trial and, because 
the UPDRS was a secondary endpoint, was not considered 
essential. The use of the insensitive DRS-II as a measure 
of cognition was also a potential drawback, but this was 
deemed to be adequate to provide an overall assessment 
of the whole trial population, with a more detailed 
neuropsychological evaluation being done in a subset of 
patients. The absence of a standard deﬁ nition of the on 
state in the protocol might also have been a limitation of 
the study, although all centres had experienced 
neurological teams familiar with doing the UPDRS and 
the comparative nature of the trial meant that any cross-
centre diﬀ erences would apply to both groups and would 
not introduce bias. 
Follow-up of PD SURG will continue for several years 
and future papers will report on the longer term outcome 
of immediate surgery versus deferred surgery; subgroup 
and prognostic factor analyses; neuropsychological 
eﬀ ects of surgery; the eﬀ ect of surgery on carers; further 
details on the procedure and longer term outcomes; and 
health economic evaluation. Surgery is likely to remain 
an important treatment option for patients with 
Parkinson’s disease, especially if the way in which deep 
brain stimulation exerts its therapeutic eﬀ ects is better 
understood, if its use can be optimised by better electrode 
placement and settings, and if patients who would have 
the greatest beneﬁ t can be better identiﬁ ed.
Contributors
AW (chief investigator), SG, TV, CJ, NQ, RM, JD, and KW (co-chief 
investigator) designed the trial. AW, NI, CR, JD, SP, and KW ran the 
trial and AW, SG, TV, NQ, and RM recruited patients. AW, SG, TV, CJ, 
NQ, RM, NI, CR, JD, SP, and KW interpreted the data and wrote the 
paper. NI and SP analysed the data. RBS designed and ran the 
neuropsychological substudy. The authors assume responsibility for 
the accuracy and completeness of the data and for the overall content 
and integrity of the paper. 
Data monitoring committee: P Sandercock (chair), C Baigent, C Counsell, 
A Mendelow, O Rascol.
Steering committee: D Chadwick (chair), M Baker, K McPherson, 
J Pickard, C Polkey, M Sculpher, C Warlow.
Articles
590 www.thelancet.com/neurology   Vol 9   June 2010
Trial management centres 
University of Birmingham (including the trial management centre at the 
Birmingham Clinical Trials Unit), Birmingham T Boodell, C E Clarke, 
J Daniels, R Gray, N Hilken, M Hyde, N Ives, G Madden, M Nixon, 
S Parsons, S Patel, C Rick, C Tomlinson, K Wheatley, A Williams; 
University of Oxford, Oxford R Fitzpatrick, A Gray, C Jenkinson (quality of 
life), E McIntosh (health economics), R Scott (neuropsychology).
Participating centres and PD SURG collaborative group members
Addenbrookes Hospital, Cambridge P Buttery, C Watts (principal 
investigator), H Watson (number of patients 12); Frenchay Hospital, 
Bristol S Gill (principal investigator), S Khan, N Heywood, L Mooney, 
N Patel, P Plaha (64); Hope Hospital, Salford P Cotton, J Dick (principal 
investigator), M Kellett, P Richardson, M Silverdale (7); John Radcliﬀ e 
Inﬁ rmary, Oxford T Aziz (principal investigator), C Fletcher, R Gregory 
(38); King’s College Hospital, London K Ashkan, C Clough, N Hulse, 
M Samuel, R Selway (principal investigator) (26); National Hospital for 
Neurology and Neurosurgery, London E Borrell, J Candalario, T Foltynie, 
M Hariz, A Lees, P Limousin (principal investigator), N Quinn, L Zrinzo 
(38); Newcastle General Hospital, Newcastle U Brechany, D Burn (principal 
investigator), A Jenkins (42); Ninewells Hospital, Dundee S Eljamel 
(principal investigator), R Swingler, C Young (4); Queen Elizabeth 
Hospital, Birmingham S Holloway, J Kausar, J Martey, R Mitchell 
(principal investigator), H Pall, A Williams (65); Queen’s Medical Centre, 
Nottingham K Anderton, S Basu (principal investigator), G Sawle, 
J Wright (2); Royal Hallamshire Hospital, Sheﬃ  eld A Franks, 
R Grunewald, C Keeley, L Nelson, M Radatz (principal investigator), 
J Rowe (19); Southern General Hospital, Glasgow L Dunn (principal 
investigator), D Grossett, T Murphy (9); Walton Centre for Neurology and 
Neurosurgery, Liverpool A Duﬀ y, P Eldridge, N Fletcher, T R K Varma 
(principal investigator) (40).
Conﬂ icts of interest
TV received travel grants from Medtronic. NQ received reimbursement 
fees from Medtronic for time spent collecting and analysing data as a 
member of the ad hoc adverse-event committee for another multicentre 
study on deep brain stimulation in Parkinson’s disease. The other 
authors have no conﬂ icts of interest. 
Acknowledgments
PD SURG was supported by funding from the UK Medical Research 
Council and Parkinson’s UK. The University of Birmingham Clinical 
Trials Unit receives support from the UK Department of Health. The 
trial also received funding from the UK Department of Health to cover 
some of the costs of surgery. We thank all the investigators who 
contributed to the trial and the patients who agreed to enter the study. 
The PDQ-39 questionnaire was developed by Crispin Jenkinson, Ray 
Fitzpatrick, and Viv Peto in 1993, who have asserted their moral rights in 
it, and the copyright, which is owned by Isis Innovation Limited. The 
questionnaire was ﬁ rst published in 1995 in the journal Quality of Life 
Research. No part of this questionnaire may be reproduced without the 
prior written consent of Isis Innovation Limited.
References
1 Williams D, Tijssen M, van Bruggen G, et al. Dopamine-
dependent changes in the functional connectivity between 
basal ganglia and cerebral cortex in humans. Brain 2002; 
125: 1558–69.
2 Poewe W. Treatments for Parkinson disease—past achievements 
and current clinical needs. Neurology 2009; 72 (7 Suppl): S65–73.
3 Mitchell IJ, Clarke CE, Boyce S, et al. Neural mechanisms 
underlying parkinsonian symptoms based upon regional uptake of 
2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine. Neuroscience 1989; 32: 213–26.
4 Bergman H, Wichmann T, DeLong MR. Reversal of experimental 
parkinsonism by lesions of the subthalamic nucleus. Science 1990; 
249: 1436–38.
5 Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the 
subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced parkinsonism in the primate. 
Mov Disord 1991; 6: 288–92.
6 Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the 
subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 
1998; 339: 1105–11.
7 Stowe RL, Wheatley K, Clarke CE, et al. Surgery for Parkinson’s 
disease: lack of reliable clinical trial evidence. 
J Neurol Neurosurg Psychiatry 2003; 74: 519–21.
8 Gibb WRG, Lees AJ. The relevance of the Lewy body to the 
pathogenesis of idiopathic Parkinson’s disease. 
J Neurol Neurosurg Psychiatry 1988; 51: 745–52.
9 Mattis S. Dementia rating scale: professional manual. Odessa, FL, 
USA: Psychological Assessment Resources, 1988. 
10 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and 
mortality. Neurology 1967; 17: 427–42.
11 Daniels J, Wheatley K, Gray R. Pairwise randomisation to balance 
within centres without possible foreknowledge of allocation. 
Control Clin Trials 2003; 24 (suppl 3S): 104–05S (abstract P23). 
12 Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The 
Parkinson’s disease questionnaire (PDQ-39): development and 
validation of a Parkinson’s disease summary index score. 
Age Ageing 1997; 26: 353–57.
13 Movement Disorder Society Task Force on Rating Scales for 
Parkinson’s Disease. The uniﬁ ed Parkinson’s disease rating scale 
(UPDRS): status and recommendations. Mov Disord 2003; 
18: 738–50.
14 Scott RB, Farmer E, Smiton A, Tovey C, Clarke M, Carpenter K. 
Methodology of neuropsychological research in multicentre 
randomized clinical trials: a model derived from the International 
Subarachnoid Aneurysm Trial. Clin Trials 2004; 1: 31–39.
15 Jenkinson C, Heﬀ erman C, Doll H, Fitzpatrick R. The Parkinson’s 
disease questionnaire (PDQ-39): evidence for a method of imputing 
missing data. Age Ageing 2006; 35: 497–502.
16 Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial 
of deep-brain stimulation for Parkinson’s disease. N Engl J Med 
2006; 355: 896–908.
17 Weaver FM, Follett K, Stern M, et al. Bilateral deep brain 
stimulation vs best medical therapy for patients with advanced 
Parkinson’s disease: a randomized controlled trial. JAMA 2009; 
301: 63–73.
18 Goetz CG, Wuu J, McDermott MP, et al. Placebo response in 
Parkinson’s disease: comparisons among 11 trials covering medical 
and surgical interventions. Mov Disord 2008; 23: 690–99.
19 Schüpbach WM, Maltête D, Houeto JL, et al. Neurosurgery at an 
earlier stage of Parkinson disease: a randomized, controlled trial. 
Neurology 2007; 68: 267–71.
20 Peto V, Jenkinson C, Fitzpatrick R. Determining minimally 
important diﬀ erences for the PDQ-39 Parkinson’s disease 
questionnaire. Age Ageing 2001; 30: 299–302.
21 Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically 
important change on the uniﬁ ed Parkinson’s disease rating scale. 
Mov Disord 2006; 21: 1200–07.
22 Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic 
nucleus deep brain stimulation: summary and meta-analysis of 
outcomes. Mov Disord 2006; 21: S290–304.
23 Weaver F, Follett K, Hur K, Ippolito D, Stern M. Deep brain 
stimulation in Parkinson disease: a metaanalysis of patient 
outcomes. J Neurosurg 2005; 103: 956–57.
24 Lanotte MM, Rizzone M, Bergamasco B, Faccani G, Melcarne A, 
Lopiano L. Deep brain stimulation of the subthalamic nucleus: 
anatomical, neurophysiological, and outcome correlations with the 
eﬀ ects of stimulation. J Neurol Neurosurg Psychiatry 2002; 
72: 53–58.
25 Starr PA, Christine CW, Theodosopoulos PV, et al. Implantation of 
deep brain stimulators into the subthalamic nucleus: technical 
approach and magnetic resonance imaging-veriﬁ ed lead locations. 
J Neurosurg 2002; 97: 370–87.
26 Hariz MI, Rehncrona S, Quinn NP, Speelman JD, Wensing C, 
Multicentre Advanced Parkinson’s Disease Deep Brain Stimulation 
Group. Multicenter study on deep brain stimulation in Parkinson’s 
disease: an independent assessment of reported adverse events at 
4 years. Mov Disord 2008; 23: 416–21.
27 Appleby BS, Duggan PS, Regenberg A, Rabins PV. Psychiatric and 
neuropsychiatric adverse events associated with deep brain 
stimulation: a meta-analysis of ten years’ experience. Mov Disord 
2007; 22: 1722–28.
28 Burkhard PR, Vingerhoets FJ, Berney A, Bogousslavsky J, 
Villemure JG, Ghika J. Suicide after successful deep brain 
stimulation for movement disorders. Neurology 2004; 63: 2170–72.
Articles
www.thelancet.com/neurology   Vol 9   June 2010 591
29 Voon V, Krack P, Lang AE, et al. A multicentre study on suicide 
outcomes following subthalamic stimulation for Parkinson’s 
disease. Brain 2008; 131: 2720–28.
30 Contarino MF, Daniele A, Sibilia AH, et al. Cognitive outcome 
5 years after bilateral chronic stimulation of subthalamic nucleus in 
patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 
2007; 78: 248–52.
31 Parsons TD, Rogers SA, Braaten AJ, Woods SP, Tröster AI. 
Cognitive sequelae of subthalamic nucleus deep brain stimulation 
in Parkinson’s disease: a meta-analysis. Lancet Neurol 2006; 
5: 578–88. 
32 Scott R, Gregory R, Hines N, et al. Neuropsychological, neurological 
and functional outcome following pallidotomy for Parkinson’s 
disease—a consecutive series of eight simultaneous bilateral and 
twelve unilateral procedures. Brain 1998; 121: 659–75.
33 Cilia R, Siri C, Marotta G, et al. Brain networks underlining verbal 
ﬂ uency decline during STN-DBS in Parkinson’s disease: an 
ECD-SPECT study. Parkinsonism Relat Disord 2007; 13: 290–94.
34 Wojtecki L, Timmermann L, Jorgens S, et al. Frequency-dependent 
reciprocal modulation of verbal ﬂ uency and motor functions in 
subthalamic deep brain stimulation. Arch Neurol 2006; 63: 1273–76.
35 Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis 
and other (mis)uses of baseline data in clinical trials. Lancet 2000; 
355: 1064–69.
36 Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for 
meta-analysis in medical research. Chichester, UK: John Wiley and 
Sons Ltd, 2000. 
